Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity

The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients

(2021) Margaret R. Jorgenson et al.   Transplant Infectious Disease

Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program

(2020) Christine Robin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events

(2020) Ralph Rogers et al.   BMC INFECTIOUS DISEASES

Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high‐risk donor seropositive/recipient seronegative heart transplant recipients

(2020) Hannah Imlay et al.   Transplant Infectious Disease

Polyomavirus and Cytomegalovirus Infections are Risk factors for Grafts Loss in Simultaneous Pancreas and Kidney Transplant

(2020) Fahad Aziz et al.   Transplant Infectious Disease

Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors

(2020) Nina Singh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a “Safe Corridor” after kidney transplantation?

(2020) Guy El Helou et al.   Transplant Infectious Disease

Risk of Opportunistic Infection in Kidney Transplant Recipients with Cytomegalovirus Infection and Associated Outcomes

(2019) Jorgenson et al.   Transplant Infectious Disease

Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

(2019) Raymund R. Razonable et al.   CLINICAL TRANSPLANTATION

Safety of Antithymocyte Globulin in Patients Undergoing Liver Transplantation With Livers From Donation After Circulatory Death Donors

(2019) Margaret R. Jorgenson et al.   ANNALS OF PHARMACOTHERAPY

The Risk of Cytomegalovirus Infection after Treatment of Acute Rejection in Renal Transplant Recipients

(2019) Margaret R Jorgenson et al.   CLINICAL TRANSPLANTATION

Single‐center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients

(2019) Shambhu Aryal et al.   Transplant Infectious Disease

The impact of recurrent cytomegalovirus infection on long‐term survival in solid organ transplant recipients

(2019) Bradley J. Gardiner et al.   Transplant Infectious Disease

Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

(2018) Bradley J Gardiner et al.   CLINICAL INFECTIOUS DISEASES

The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

(2018) Camille N. Kotton et al.   TRANSPLANTATION

Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis

(2018) Napat Leeaphorn et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation

(2015) Lionel Couzi et al.   Frontiers in Immunology

Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation

(2013) R. R. Razonable et al.   CLINICAL MICROBIOLOGY REVIEWS

Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study

(2013) Susanne Stoelben et al.   TRANSPLANT INTERNATIONAL

Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients

(2011) Tomáš Reischig et al.   ANTIVIRAL THERAPY

The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase

(2011) T. Goldner et al.   JOURNAL OF VIROLOGY

Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients

(2010) A. Åsberg et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246

(2010) P. Lischka et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY